InfuSystem (NYSE:INFU) Upgraded at

InfuSystem (NYSE:INFUGet Rating) was upgraded by research analysts at from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

InfuSystem Price Performance

Shares of INFU opened at $8.18 on Thursday. InfuSystem has a 1-year low of $6.10 and a 1-year high of $18.17. The firm has a market capitalization of $168.97 million, a P/E ratio of 818.82 and a beta of 1.17. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.86 and a quick ratio of 1.48.

About InfuSystem

(Get Rating)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Read More

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with's FREE daily email newsletter.